The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The prognostic significance of lymphovascular invasion in invasive breast carcinoma
Open accessAbstract
BACKGROUND: Although lymphovascular invasion (LVI) has been associated with a poor outcome in patients with breast cancer, it is not included in most internationally recognized staging systems, including the American Joint Committee on Cancer tumor, lymph node, metastasis (TNM) classification. This is mainly because it remains unclear whether the presence of LVI is an independent, high‐risk criterion in clinically relevant staging subgroups. METHODS: The current study was based on a large and well characterized consecutive series of patients who had operable (pathologic T1 [pT1]‐pT2, pathologic N0 [pN0]‐pN3, M0) breast cancer (3812 informative cases) who were treated according to standard protocols at a single institution and who had long‐term follow‐up to assess the prognostic value of definite LVI in clinically and molecularly relevant staging subgroups. RESULTS: LVI was strongly associated with both breast cancer‐specific survival (BCSS) and distant metastasis‐free survival (DMFS) in the entire series and in different subgroups. Multivariate analyses identified LVI as an independent predictor of both BCSS and DMFS in patients with operable breast cancer overall; in the TNM clinical subgroups pT1a‐pT1c/pN0 and pT2/pN0; and in the molecular classes estrogen receptor (ER)‐positive, ER‐negative, human epidermal growth factor 2 [HER2]‐negative, and triple‐negative. In patients who had lymph node‐negative tumors, LVI could be used as a high‐risk criterion providing survival disadvantage equivalent to that provided by 1 or 2 involved lymph nodes (pN0 to pN1) and to that provided by 1 size category (pT1 to pT2). The use of immunohistochemistry for detecting an endothelial‐specific marker contributed to the prognostic significance of LVI when applied to routine LVI negative/possible cases. CONCLUSIONS: LVI provided a strong predictor of outcome in patients with invasive breast cancer and should be incorporated into breast cancer staging systems. Cancer 2012. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationPathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
American Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Self-citationBreast cancer prognostic classification in the molecular era: the role of histological grade
Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2607 · Cited by 1,003
Self-citationWirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
Walker, R. A. (2005) · Histopathology · doi:10.1111/j.1365-2559.2004.02026.x · Cited by 839
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Rosen, P. P. (1997) · Cited by 820
Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma
Rakha, E. A., El-Sayed, M. E., Lee, A. H. S., Elston, C. W., Grainge, M. J., Hodi, Z., Blamey, R. W., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5986 · Cited by 628
Self-citationLiljegren, G., Holmberg, L., Bergh, J., Lindgren, A., Tabár, L., Nordgren, H., & Adami, H. O. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2326 · Cited by 548
Veronesi, U., Marubini, E., Vecchio, M. D., Manzari, A., Andreola, S., Greco, M., Luini, A., Merson, M., Saccozzi, R., Rilke, F., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.1.19 · Cited by 505
ELLIS, I. O., GALEA, M., BROUGHTON, N., LOCKER, A., BLAMEY, R. W., & ELSTON, C. W. (1992) · Histopathology · doi:10.1111/j.1365-2559.1992.tb01032.x · Cited by 487
Self-citationWishart, G. C., Azzato, E. M., Greenberg, D. C., Rashbass, J., Kearins, O., Lawrence, G., Caldas, C., & Pharoah, P. D. (2010) · Breast Cancer Research · doi:10.1186/bcr2464 · Cited by 418
Self-citationWorld Health Organization Classification of Tumors
Tavassoli, F. A. (2003) · Medical Entomology and Zoology · Cited by 376
Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1239 · Cited by 355
Rakha, E., Putti, T., Abd El‐Rehim, D., Paish, C., Green, A., Powe, D., Lee, A., Robertson, J., & Ellis, I. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311
Self-citationPINDER, S. E., ELLIS, I. O., GALEA, M., O'ROUKE, S., BLAMEY, R. W., & ELSTON, C. W. (1994) · Histopathology · doi:10.1111/j.1365-2559.1994.tb01269.x · Cited by 287
Self-citationPrognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer
Schoppmann, S. F., Bayer, G., Aumayr, K., Taucher, S., Geleff, S., Rudas, M., Kubista, E., Hausmaninger, H., Samonigg, H., Gnant, M., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133355.48672.22 · Cited by 281
Mook, S., Schmidt, M. K., Rutgers, E. J., van de Velde, A. O., Visser, O., Rutgers, S. M., Armstrong, N., van't Veer, L. J., & Ravdin, P. M. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70254-2 · Cited by 177
den Eynden, G. G. V., der Auwera, I. V., Laere, S. V., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603152 · Cited by 143
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Carlson, R. W., Brown, E., Burstein, H. J., Gradishar, W. J., Hudis, C. A., Loprinzi, C. L., Mamounas, E. P., Perez, E. A., Pritchard, K. I., Ravdin, P. M., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2001 · Cited by 140
Lee, A. H. S., Pinder, S. E., Macmillan, R. D., Mitchell, M., Ellis, I. O., Elston, C. W., & Blamey, R. W. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.10.021 · Cited by 137
Self-citationEjlertsen, B., Jensen, M., Rank, F. E., Rasmussen, B., Christiansen, P., Kroman, N. T., Kvistgaard, M. E., Overgaard, M., Toftdahl, D. B., & Mouridsen, H. T. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp090 · Cited by 112
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
Aleskandarany, M. A., Rakha, E. A., Macmillan, R. D., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1028-3 · Cited by 109
Self-citationde Mascarel, I., Bonichon, F., Durand, M., Mauriac, L., MacGrogan, G. M., Soubeyran, I., Picot, V., Avril, A., Coindre, J., & Trojani, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00344-4 · Cited by 97
Mohammed, R. A., Martin, S. G., Mahmmod, A. M., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2810 · Cited by 93
Self-citationCheng, S. H., Horng, C., Clarke, J. L., Tsou, M.-H., Tsai, S. Y., Chen, C.-M., Jian, J. J., Liu, M.-C., West, M., Huang, A. T., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.11.015 · Cited by 60
Ragage, F., Debled, M., MacGrogan, G. M., et al. (2010) · Cancer · doi:10.1002/cncr.25137 · Cited by 36
Debled, M., de Mascarel, I., Brouste, V., Mauriac, L., & MacGrogan, G. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp490 · Cited by 9
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Metastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392
Metadata
- Authors
- Rakha, E. A., Martin, S., Lee, A. H. S., Morgan, D., Pharoah, P. D. P., Hodi, Z., MacMillan, D., & Ellis, I. O.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-12-16
- Volume
- 118
- Issue
- 15
- Pages
- 3670-3680
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1545734177
- Cited by
- 271
- References
- 34
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.